P116: Analysis of FDA Warning Letters (2020–2025): Recurring CAPA Failures Under QSR and Implications for QMSR Transition
Poster Presenter
Mansi Gupta
Quality Systems Specialists
Tolmar, MS Regulatory Affairs, Northeastern University United States
Objectives
To evaluate recurring CAPA-related deficiencies cited in FDA medical device warning letters (2020–2025) under 21 CFR 820 and analyze their regulatory implications for industry preparedness as the Quality System Regulation transitions to the QMSR framework.
Method
A systematic assessment was conducted of FDA medical device warning letters issued between 2020 and 2025 that cited CAPA breaches under 21 CFR 820.100. To find recurrent enforcement trends relevant to the QMSR transition, observations were sorted by firm size, device categorization, and deficiencies
Results
A review of 127 FDA medical device warning letters issued between 2020 and 2025, citing 21 CFR 820.100, revealed five consistent CAPA failure patterns.
Inadequate root cause analysis was the most common deficiency (68%). Investigations frequently concluded at proximate causes such as "operator error" or "equipment malfunction" without documenting deeper systemic contributors, resulting in corrective actions that addressed symptoms rather than underlying process weaknesses.
52% of warning letters blamed insufficient effectiveness verification. Several cases showed recurring quality problems after CAPA closure, and corrective steps were carried out without objective proof of long-term recurrence prevention.
In 47% of citations, manufacturers did not demonstrate effective data trending or preventive action processes to identify and address systemic quality risks.
Documentation deficiencies were identified in 41% of warning letters, including incomplete investigation records, unclear decision rationale, and lack of verifiable evidence supporting CAPA implementation and effectiveness.
In 23% of cases, supplier-related CAPA management deficiencies were found, which were indicative of insufficient evaluation of the impact on cross-products and little supervision of supplier corrective actions.
89% of citations were for Class II and III medical devices, and 71% of cited firms were small-to-mid-sized manufacturers (less than 500 employees).
When taken as a whole, these results demonstrate that repeated CAPA execution errors under QSR are indicative of structural deficiencies in quality governance that are directly related to the more stringent risk-based and documentation requirements under QMSR.
Conclusion
This analysis shows that recurrent CAPA deficiencies reported under 21 CFR 820.100 are persistent execution-level defects in medical device quality systems subject to the Quality System Regulation (QSR), not isolated compliance incidents. Systemic weaknesses in CAPA governance are seen in the number of instances of poor trending and preventative action (47%), inadequate root cause analysis (68%), insufficient effectiveness verification (52%), documentation gaps (41%), and supplier supervision failures (23%).
These results show that inconsistent application of fundamental quality system principles, such as risk-based investigation, objective verification of corrective actions, data-driven preventive mechanisms, and traceable documentation controls, is more likely to cause enforcement risk than regulatory ambiguity.
Regulatory expectations will place a greater emphasis on documented risk management integration, quantifiable CAPA effectiveness, improved supplier controls, and inspection-ready quality records as the FDA moves to the Quality Management System Regulation (QMSR), which incorporates ISO 13485:2016 by reference. It appears that past enforcement trends provide predictive information about QMSR implementation risk areas, as seen by the alignment between documented QSR failure patterns and enhanced ISO 13485 criteria.
Manufacturers are likely to lower regulatory exposure and improve sustainable quality performance if they proactively reinforce investigation depth, effectiveness criteria, data trending, and supplier corrective action management before QMSR enforcement.
These results support the hypothesis that historical CAPA enforcement patterns under QSR directly inform strategic readiness priorities for QMSR transition.
